Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 20
2003 11
2004 12
2005 11
2006 13
2007 19
2008 9
2009 13
2010 20
2011 16
2012 26
2013 17
2014 23
2015 26
2016 26
2017 29
2018 25
2019 30
2020 36
2021 41
2022 41
2023 34
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

461 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.
Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, Iwata H, Masuda N, Torregroza Otero M, Gokmen E, Loi S, Guo Z, Zhou X, Karantza V, Pan W, Schmid P; KEYNOTE-355 Investigators. Cortes J, et al. N Engl J Med. 2022 Jul 21;387(3):217-226. doi: 10.1056/NEJMoa2202809. N Engl J Med. 2022. PMID: 35857659 Clinical Trial.
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, Iwata H, Masuda N, Otero MT, Gokmen E, Loi S, Guo Z, Zhao J, Aktan G, Karantza V, Schmid P; KEYNOTE-355 Investigators. Cortes J, et al. Lancet. 2020 Dec 5;396(10265):1817-1828. doi: 10.1016/S0140-6736(20)32531-9. Lancet. 2020. PMID: 33278935 Clinical Trial.
Orexin 2 receptor-selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients.
Evans R, Kimura H, Alexander R, Davies CH, Faessel H, Hartman DS, Ishikawa T, Ratti E, Shimizu K, Suzuki M, Tanaka S, Yukitake H, Dauvilliers Y, Mignot E. Evans R, et al. Among authors: ishikawa t. Proc Natl Acad Sci U S A. 2022 Aug 30;119(35):e2207531119. doi: 10.1073/pnas.2207531119. Epub 2022 Aug 22. Proc Natl Acad Sci U S A. 2022. PMID: 35994639 Free PMC article.
Pembrolizumab plus chemotherapy in Japanese patients with triple-negative breast cancer: Results from KEYNOTE-355.
Hattori M, Masuda N, Takano T, Tsugawa K, Inoue K, Matsumoto K, Ishikawa T, Itoh M, Yasojima H, Tanabe Y, Yamamoto K, Suzuki M, Pan W, Cortes J, Iwata H. Hattori M, et al. Among authors: ishikawa t. Cancer Med. 2023 May;12(9):10280-10293. doi: 10.1002/cam4.5757. Epub 2023 Mar 14. Cancer Med. 2023. PMID: 36916728 Free PMC article. Clinical Trial.
Neoadjuvant therapy for gastrointestinal stromal tumor.
Ishikawa T, Kanda T, Kameyama H, Wakai T. Ishikawa T, et al. Transl Gastroenterol Hepatol. 2018 Jan 10;3:3. doi: 10.21037/tgh.2018.01.01. eCollection 2018. Transl Gastroenterol Hepatol. 2018. PMID: 29441368 Free PMC article. Review.
Axoneme Structure from Motile Cilia.
Ishikawa T. Ishikawa T. Cold Spring Harb Perspect Biol. 2017 Jan 3;9(1):a028076. doi: 10.1101/cshperspect.a028076. Cold Spring Harb Perspect Biol. 2017. PMID: 27601632 Free PMC article. Review.
Structure of Motile Cilia.
Ishikawa T. Ishikawa T. Subcell Biochem. 2022;99:471-494. doi: 10.1007/978-3-031-00793-4_15. Subcell Biochem. 2022. PMID: 36151386
461 results